Epigenomics Licenses Septin9 Biomarker to Companion Dx Lab for Colorectal Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today announced Companion Dx Reference Labs has obtained the rights to establish and commercialize a colorectal cancer test using the methylated Septin9 biomarker.

Under the terms of the deal, Companion Dx will be able to use Epigenomics' biomarker to create a blood-based, laboratory developed test, while Epigenomics is entitled to double-digit royalties on sales of the test. Other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."